HIV-Infektion: Moderne antiretrovirale Therapie

Literatur

• 1 Department of Health and Human Services (DHHS): Guidelines for the use of antiretroviral agents in HIV-1 infected adults and adolescents. March 23rd, 2004 http://www.aidsinfo.nih.gov/guidelines/adult. 
• 2 Deutsch-Östereichische Leitlinien zur antiretroviralen Therapie der HIV-Infektion. Dtsch Med Wochenschr 2003; 128: S7-S18 (überarbeitete Version: http://www.rki.de). 
• 3 EACS Europe Guidelines Group: European Guidelines for the clinical management and treatment of HIV-infected adults in Europe. AIDS 2003; 17 (Suppl 2): S3-S26 (http://www.eacs.ws). 
• 4 Furrer H, Battegay M, Spirig R. et al . Herausforderungen bei der HIV-Langzeitbetreuung.  Dtsch Med Wochenschr. 2003;  128 1064-1069
• 5 Gallant J E, Rodriguez A, Weinberg W. et al . Early non-response to tenofovir DF (TDF) + Abacavir (ABC) and lamivudine (3TC) in a randomized trial compared to efavirenz (EFV) + ABC + 3TC: ESS30009 unplanned interim analysis. 43rd Interscience Conference on Antimicrobial Agents and Chemotherapy, Chicago, IL, September 16, 2003. (Abstract H-1722a). 
• 6 Gulick R M, Ribaudo H J, Shikuma C M. et al . Triple-nucleoside regimens versus Efavirenz-containing regimens for the initial treatment of HIV-1 infection.  N Eng J Med. 2004;  350 1850-61
• 7 Kempf D J, Rode R A, Xu Y. et al . The duration of viral suppression during protease inhibitor therapy for HIV-1 infection is predicted by plasma HIV-1 RNA at the nadir.  AIDS. 1998;  12 F9-F14
• 8 Palella F J Jr, Delaney K M, Moorman A C. et al . Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. HIV Outpatient Study Investigators.  N Engl J Med. 1998;  338 853-60
• 9 The EuroGuidelines Group for HIV Resistance . Clinical and laboratory guidelines for the use of HIV-1 drug resistance testing as part of treatment management: recommendations for the European setting. The EuroGuidelines Group for HIV resistance.  AIDS. 2001;  15 309-320